Reliable measurements of the β -amyloid pool in blood could help in the early diagnosis of AD

International Journal of Alzheimer's Disease

Volumn , Issue , 2012, Pages

  Pesini, Pedro ^a   Pérez Grijalba, Virginia ^a   Monleón, Inmaculada ^a   Boada, Mercè ^b   Tárraga, Lluís ^b   Martínez Lage, Pablo ^b   San José, Itziar ^a   Sarasa, Manuel ^a  

^a Araclon Biotech Ltd   (Spain)

^b Institut Català de Neurciències Aplicades   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42];

AGED; ALZHEIMER DISEASE; AMNESIA; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RELIABILITY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

EID: 84866246320     PISSN: None     EISSN: 20900252     Source Type: Journal    
DOI: 10.1155/2012/604141     Document Type: Article

References (51)

1. Nelson P. T., Braak H., Markesbery W. R., Neuropathology and cognitive impairment in alzheimer disease: a complex but coherent relationship. Journal of Neuropathology and Experimental Neurology 2009 68 1 1 14 2-s2.0-64049098761 10.1097/NEN.0b013e3181919a48
2. Shaw L. M., Vanderstichele H., Knapik-Czajka M., Clark C. M., Aisen P. S., Petersen R. C., Blennow K., Soares H., Simon A., Lewczuk P., Dean R., Siemers E., Potter W., Lee V. M. Y., Trojanowski J. Q., Cerebrospinal fluid biomarker signature in alzheimer's disease neuroimaging initiative subjects. Annals of Neurology 2009 65 4 403 413 2-s2.0-65249159879 10.1002/ana.21610
3. Hansson O., Zetterberg H., Buchhave P., Andreasson U., Londos E., Minthon L., Blennow K., Prediction of Alzheimer's disease using the CSF A β 42/A β 40 ratio in patients with mild cognitive impairment. Dementia and Geriatric Cognitive Disorders 2007 23 5 316 320 2-s2.0-34247384609 10.1159/000100926
4. Lewczuk P., Kornhuber J., Vanderstichele H., Vanmechelen E., Esselmann H., Bibl M., Wolf S., Otto M., Reulbach U., Kolsch H., Jessen F., Schroder J., Schonknecht P., Hampel H., Peters O., Weimer E., Perneczky R., Jahn H., Luckhaus C., Lamla U., Supprian T., Maler J. M., Wiltfang J., Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. Neurobiology of Aging 2008 29 6 812 818 10.1016/j. neurobiolaging.2006.12.010
5. Mattsson N., Zetterberg H., Hansson O., Andreasen N., Parnetti L., Jonsson M., Herukka S.-K., Van Der Flier W. M., Blankenstein M. A., Ewers M., Rich K., Kaiser E., Verbeek M., Tsolaki M., Mulugeta E., Rosén E., Aarsland D., Jelle Visser P., Schröder J., Marcusson J., De Leon M., Hampel H., Scheltens P., Pirttilä T., Wallin A., Jonhagen M. E., Minthon L., Winblad B., Blennow K., CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. Journal of the American Medical Association 2009 302 4 385 393 10.1001/jama.2009.1064
6. Hansson O., Zetterberg H., Vanmechelen E., Vanderstichele H., Andreasson U., Londos E., Wallin A., Minthon L., Blennow K., Evaluation of plasma A β 40 and A β 42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiology of Aging 2010 31 3 357 367 2-s2.0-74149089257 10.1016/j.neurobiolaging.2008.03.027
7. Shibata M., Yamada S., Ram Kumar S., Calero M., Bading J., Frangione B., Holtzman D. M., Miller C. A., Strickland D. K., Ghiso J., Zlokovic B. V., Clearance of Alzheimer's amyloid- β 1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. Journal of Clinical Investigation 2000 106 12 1489 1499 2-s2.0-0034521392
8. Tanzi R. E., Moir R. D., Wagner S. L., Clearance of Alzheimer's A β peptide: the many roads to perdition. Neuron 2004 43 5 605 608 2-s2.0-4444276735 10.1016/j.neuron.2004.08.024
9. Deane R., Bell R. D., Sagare A., Zlokovic B. V., Clearance of amyloid- β peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS and Neurological Disorders 2009 8 1 16 30 2-s2.0-65649105035 10.2174/187152709787601867
10. Zetterberg H., Is plasma amyloid- β a reliable biomarker for Alzheimer's disease? Recent Patents on CNS Drug Discovery 2008 3 2 109 111 2-s2.0-49149095666 10.2174/157488908784534595
11. Okereke O. I., Xia W., Irizarry M. C., Sun X., Qiu W. Q., Fagan A. M., Mehta P. D., Hyman B. T., Selkoe D. J., Grodstein F., Performance characteristics of plasma amyloid- β 40 and 42 assays. Journal of Alzheimer's Disease 2009 16 2 277 285 2-s2.0-60349123096 10.3233/JAD-2009-0948
12. Cedazo-Minguez A., Winblad B., Biomarkers for Alzheimer's disease and other forms of dementia: clinical needs, limitations and future aspects. Experimental Gerontology 2010 45 1 5 14 2-s2.0-72149104756 10.1016/j.exger.2009. 09.008
13. Schupf N., Patel B., Pang D., Zigman W. B., Silverman W., Mehta P. D., Mayeux R., Elevated plasma β -amyloid peptide A β 42 levels, incident dementia, and mortality in Down syndrome. Archives of Neurology 2007 64 7 1007 1013 2-s2.0-34447275455 10.1001/archneur.64.7.1007
14. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T. D., Hardy J., Hutton M., Kukull W., Larson E., Levy-Lahad E., Viitanen M., Peskind E., Poorkaj P., Schellenberg G., Tanzi R., Wasco W., Lannfelt L., Selkoe D., Younkin S., Secreted amyloid β -protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Medicine 1996 2 8 864 870 2-s2.0-16044373524 10.1038/nm0896-864
15. Assini A., Cammarata S., Vitali A., Colucci M., Giliberto L., Borghi R., Inglese M. L., Volpe S., Ratto S., Dagna-Bricarelli F., Baldo C., Argusti A., Odetti P., Piccini A., Tabaton M., Plasma levels of amyloid β -protein 42 are increased in women with mild cognitive impairment. Neurology 2004 63 5 828 831 2-s2.0-4644267911
16. Mayeux R., Honig L. S., Tang M. X., Manly J., Stern Y., Schupf N., Mehta P. D., Plasma A β 40 and A β 42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 2003 61 9 1185 1190 2-s2.0-0242412140
17. Ertekin-Taner N., Younkin L. H., Yager D. M., Parfitt F., Baker M. C., Asthana S., Hutton M. L., Younkin S. G., Graff-Radford N. R., Plasma amyloid β protein is elevated in late-onset Alzheimer disease families. Neurology 2008 70 8 596 606 2-s2.0-39749090577 10.1212/01.wnl.0000278386.00035.21
18. Blasko I., Jellinger K., Kemmler G., Krampla W., Jungwirth S., Wichart I., Tragl K. H., Fischer P., Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine. Neurobiology of Aging 2008 29 1 1 11 2-s2.0-36048982129 10.1016/j.neurobiolaging.2006.09.002
19. Schupf N., Tang M. X., Fukuyama H., Manly J., Andrews H., Mehta P., Ravetch J., Mayeux R., Peripheral A β subspecies as risk biomarkers of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 2008 105 37 14052 14057 2-s2.0-52949118083 10.1073/pnas.0805902105
20. Xia W., Yang T., Shankar G., Smith I. M., Shen Y., Walsh D. M., Selkoe D. J., A specific enzyme-linked immunosorbent assay for measuring β -amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer Disease. Archives of Neurology 2009 66 2 190 199 2-s2.0-60549107033 10.1001/archneurol.2008.565
21. Sobów T., Flirski M., Kloszewska I., Liberski P. P., Plasma levels of A β peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease. Acta Neurobiologiae Experimentalis 2005 65 2 117 124 2-s2.0-21044447551
22. Kawarabayashi T., Younkin L. H., Saido T. C., Shoji M., Ashe K. H., Younkin S. G., Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer's disease. Journal of Neuroscience 2001 21 2 372 381 2-s2.0-0035863055
23. Biere A. L., Ostaszewski B., Stimson E. R., Hyman B. T., Maggio J. E., Selkoe D. J., Amyloid β -peptide is transported on lipoproteins and albumin in human plasma. Journal of Biological Chemistry 1996 271 51 32916 32922 2-s2.0-16944364644 10.1074/jbc.271.51.32916
24. Rogers J., Li R., Mastroeni D., Grover A., Leonard B., Ahern G., Cao P., Kolody H., Vedders L., Kolb W. P., Sabbagh M., Peripheral clearance of amyloid β peptide by complement C3-dependent adherence to erythrocytes. Neurobiology of Aging 2006 27 12 1733 1739 2-s2.0-33750031006 10.1016/j.neurobiolaging.2005.09.043
25. Matsubara E., Sekijima Y., Tokuda T., Urakami K., Amari M., Shizuka-Ikeda M., Tomidokoro Y., Ikeda M., Kawarabayashi T., Harigaya Y., Ikeda S. I., Murakami T., Abe K., Otomo E., Hirai S., Frangione B., Ghiso J., Shoji M., Soluble A β homeostasis in AD and DS: impairment of anti-amyloidogenic protection by lipoproteins. Neurobiology of Aging 2004 25 7 833 841 2-s2.0-4544307730 10.1016/j.neurobiolaging.2003.10.004
26. Blennow K., Hampel H., Weiner M., Zetterberg H., Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nature Reviews Neurology 2010 6 3 131 144 2-s2.0-77949423619 10.1038/nrneurol.2010.4
27. Scheltens P., Leys D., Barkhof F., Huglo D., Weinstein H. C., Vermersch P., Kuiper M., Steinling M., Wolters E. C., Valk J., Atrophy of medial temporal lobes on MRI in 'probable' Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. Journal of Neurology Neurosurgery and Psychiatry 1992 55 10 967 972 2-s2.0-0026759348
28. Alegret M., Boada-Rovira M., Vinyes-Junqué G., Valero S., Espinosa A., Hernández I., Modinos G., Rosende-Roca M., Mauleon A., Becker J. T., Tárraga L., Detection of visuoperceptual deficits in preclinical and mild Alzheimer's disease. Journal of Clinical and Experimental Neuropsychology 2009 31 7 860 867 2-s2.0-74949113594 10.1080/13803390802595568
29. Hixson J. E., Vernier D. T., Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. Journal of Lipid Research 1990 31 3 545 548 2-s2.0-0025257612
30. Barnhart H. X., Haber M., Song J., Overall concordance correlation coefficient for evaluating agreement among multiple observers. Biometrics 2002 58 4 1020 1027 2-s2.0-0036968848
31. Kuo Y. M., Emmerling M. R., Lampert H. C., Hempelman S. R., Kokjohn T. A., Woods A. S., Cotter R. J., Roher A. E., High levels of circulating A β 42 are sequestered by plasma proteins in Alzheimer's disease. Biochemical and Biophysical Research Communications 1999 257 3 787 791 2-s2.0-0033590975 10.1006/bbrc.1999.0552
32. Mehta P. D., Pirttilä T., Mehta S. P., Sersen E. A., Aisen P. S., Wisniewski H. M., Plasma and cerebrospinal fluid levels of amyloid β proteins 1-40 and 1- 42 in Alzheimer disease. Archives of Neurology 2000 57 1 100 105 2-s2.0-0033975837
33. Petersen R. C., Aisen P. S., Beckett L. A., Donohue M. C., Gamst A. C., Harvey D. J., Jack C. R. Jr, Jagust W. J., Shaw L. M., Toga A. W., Trojanowski J. Q., Weiner M. W., Alzheimer's disease neuroimaging initiative (ADNI): clinical characterization. Neurology 2010 74 3 201 209 2-s2.0-74949097405 10.1212/WNL.0b013e3181cb3e25
34. Sureshbabu N., Kirubagaran R., Jayakumar R., Surfactant-induced conformational transition of amyloid β -peptide. European Biophysics Journal 2009 38 4 355 367 2-s2.0-62949142989 10.1007/s00249-008-0379-8
35. Vemuri P., Wiste H. J., Weigand S. D., Shaw L. M., Trojanowski J. Q., Weiner M. W., Knopman D. S., Petersen R. C., Jack C. R. Jr, MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 2009 73 4 294 301 2-s2.0-68249111164 10.1212/WNL.0b013e3181af79fb
36. Lopez O. L., Kuller L. H., Mehta P. D., Becker J. T., Gach H. M., Sweet R. A., Chang Y. F., Tracy R., DeKosky S. T., Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology 2008 70 19 1664 1671 2-s2.0-43149101531 10.1212/01.wnl.0000306696.82017.66
37. Szabo P., Relkin N., Weksler M. E., Natural human antibodies to amyloid beta peptide. Autoimmunity Reviews 2008 7 6 415 420 2-s2.0-51749103554 10.1016/j.autrev.2008.03.007
38. van Oijen M., Hofman A., Soares H. D., Koudstaal P. J., Breteler M. M., Plasma A β 1-40 and A β 1-42 and the risk of dementia: a prospective case-cohort study. Lancet Neurology 2006 5 8 655 660 2-s2.0-33745959062 10.1016/S1474-4422(06)70501-4
39. Jack C. R. Jr, Lowe V. J., Weigand S. D., Wiste H. J., Senjem M. L., Knopman D. S., Shiung M. M., Gunter J. L., Boeve B. F., Kemp B. J., Weiner M., Petersen R. C., Serial PIB and MRI in normal, mild cognitive impairment and Alzheimers disease: implications for sequence of pathological events in Alzheimers disease. Brain 2009 132 5 1355 1365 2-s2.0-66549106850 10.1093/brain/awp062
40. Giedraitis V., Sundelöf J., Irizarry M. C., Gårevik N., Hyman B. T., Wahlund L. O., Ingelsson M., Lannfelt L., The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. Neuroscience Letters 2007 427 3 127 131 2-s2.0-35448942648 10.1016/j.neulet. 2007.09.023
41. Zlokovic B. V., Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends in Neurosciences 2005 28 4 202 208 2-s2.0-13544268809 10.1016/j.tins.2005.02.001
42. Fagan A. M., Head D., Shah A. R., Marcus D., Mintun M., Morris J. C., Holtzman D. M., Decreased cerebrospinal fluid A β 42 correlates with brain atrophy in cognitively normal elderly. Annals of Neurology 2009 65 2 176 183 2-s2.0-62549122091 10.1002/ana.21559
43. Vemuri P., Wiste H. J., Weigand S. D., Shaw L. M., Trojanowski J. Q., Weiner M. W., Knopman D. S., Petersen R. C., Jack C. R. Jr, MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology 2009 73 4 287 293 2-s2.0-68249090572 10.1212/WNL.0b013e3181af79e5
44. Frisoni G. B., Fox N. C., Jack C. R. Jr, Scheltens P., Thompson P. M., The clinical use of structural MRI in Alzheimer disease. Nature Reviews Neurology 2010 6 2 67 77 2-s2.0-76849095847 10.1038/nrneurol.2009.215
45. Jagust W. J., Landau S. M., Shaw L. M., Trojanowski J. Q., Koeppe R. A., Reiman E. M., Foster N. L., Petersen R. C., Weiner M. W., Price J. C., Mathis C. A., Relationships between biomarkers in aging and dementia. Neurology 2009 73 15 1193 1199 2-s2.0-70350152831 10.1212/WNL.0b013e3181bc010c
46. Hampel H., Bürger K., Teipel S. J., Bokde A. L. W., Zetterberg H., Blennow K., Core candidate neurochemical and imaging biomarkers of Alzheimer's diseaseThis paper was presented in part by the 1st author at the 10th International Conference of Alzheimer's Disease and Related Disorders (ICAD), Madrid, Spain, July 2006, as an invited plenary lecture. Alzheimer's and Dementia 2008 4 1 38 48 2-s2.0-38049179307 10.1016/j.jalz.2007.08.006
47. Graff-Radford N. R., Crook J. E., Lucas J., Boeve B. F., Knopman D. S., Ivnik R. J., Smith G. E., Younkin L. H., Petersen R. C., Younkin S. G., Association of low plasma A β 42/A β 40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Archives of Neurology 2007 64 3 354 362 2-s2.0-33947282076 10.1001/archneur.64.3.354
48. Freeman S. H., Raju S., Hyman B. T., Frosch M. P., Irizarry M. C., Plasma A β levels do not reflect brain A β levels. Journal of Neuropathology and Experimental Neurology 2007 66 4 264 271 2-s2.0-34147105393 10.1097/NEN.0b013e31803d3ae4
49. Sundelof J., Giedraitis V., Irizarry M. C., Sundstrom J., Ingelsson E., Ronnemaa E., Arnlov J., Gunnarsson M. D., Hyman B. T., Basun H., Ingelsson M., Lannfelt L., Kilander L., Plasma β amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Archives of Neurology 2008 65 2 256 263 10.1001/archneurol.2007.57
50. Lewczuk P., Kornhuber J., Vanmechelen E., Peters O., Heuser I., Maier W., Jessen F., Burger K., Hampel H., Frolich L., Henn F., Falkai P., Ruther E., Jahn H., Luckhaus C., Perneczky R., Schmidtke K., Schroder J., Kessler H., Pantel J., Gertz H.-J., Vanderstichele H., de Meyer G., Shapiro F., Wolf S., Bibl M., Wiltfang J., Amyloid β peptides in plasma in early diagnosis of Alzheimer's disease: a multicenter study with multiplexing. Experimental Neurology 2010 223 2 366 370 10.1016/j.expneurol.2009.07.024
51. Lambert J. C., Schraen-Maschke S., Richard F., Fievet N., Rouaud O., Berr C., Dartigues J. F., Tzourio C., Alpérovitch A., Buée L., Amouyel P., Association of plasma amyloid β with risk of dementia: the prospective Three-City Study. Neurology 2009 73 11 847 853 2-s2.0-70349576339 10.1212/WNL.0b013e3181b78448